Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $46.43

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given a consensus rating of “Buy” by the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $46.43.

DNTH has been the topic of a number of research reports. Oppenheimer lifted their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth about $556,000. Barclays PLC increased its position in shares of Dianthus Therapeutics by 390.5% in the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after buying an additional 33,185 shares in the last quarter. HighVista Strategies LLC purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at approximately $542,000. State Street Corp lifted its holdings in Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after purchasing an additional 413,425 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Dianthus Therapeutics by 142.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after buying an additional 97,362 shares in the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Down 4.8 %

Shares of DNTH opened at $21.21 on Tuesday. The business has a 50-day simple moving average of $23.16 and a two-hundred day simple moving average of $26.21. Dianthus Therapeutics has a 52 week low of $16.72 and a 52 week high of $33.77. The stock has a market cap of $627.75 million, a price-to-earnings ratio of -8.48 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. On average, equities analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.